Combination immunotherapy regimens in China — the growing adoption of PD-1/PD-L1 inhibitor combinations with chemotherapy, anti-VEGF agents, CTLA-4 inhibitors, and novel agents creating multi-drug regimens that expand per-patient treatment costs and market value — represents a key market expansion dynamic within the Chinese immunotherapy market, with the China Immunotherapy Drugs Market reflecting combination therapy as a commercial market growth driver.

PD-1 plus bevacizumab or apatinib in China — the widespread Chinese clinical adoption of PD-1 checkpoint inhibitors combined with antiangiogenic agents (bevacizumab, apatinib — Chinese-developed VEGFR-2 inhibitor) for HCC, NSCLC, and other cancers — represents a particularly Chinese clinical practice pattern from the high HCC incidence and the availability of Chinese-developed apatinib as an affordable antiangiogenic partner. The ORIENT-32 trial (sintilimab plus bevacizumab for HCC), RESCUE trial (camrelizumab plus apatinib for HCC), and multiple similar Chinese combination programs demonstrate the antiangiogenic-immunotherapy combination market.

Chemotherapy plus PD-1 combination regimens — the standard-of-care transition across multiple Chinese cancer types (NSCLC, gastric cancer, esophageal, NPC) from chemotherapy alone to chemotherapy plus PD-1 checkpoint inhibitor — represents the largest volume immunotherapy combination market in China. The Chinese clinical guideline adoption of PD-1 plus chemotherapy as standard first-line for qualifying patients creating the institutional prescribing pattern that drives combination therapy volume.

Dual checkpoint blockade in China — the emerging market for PD-1 plus CTLA-4 combination (and bispecific alternatives like cadonilimab) for advanced cancer patients representing the premium combination therapy market — creates the highest-cost treatment tier. The approval of ipilimumab/nivolumab combinations for specific indications and the domestic cadonilimab approval demonstrating Chinese dual checkpoint blockade market development.

Do you think the rapid clinical adoption of combination immunotherapy regimens in China is driven primarily by clinical evidence or by commercial incentives from multiple drug sales, and how should Chinese clinical guidelines better evaluate these combinations?

FAQ

What chemotherapy-immunotherapy combinations are most commonly used in China? China standard combination immunotherapy regimens: Lung cancer (NSCLC): squamous NSCLC: sintilimab/camrelizumab/tislelizumab + carboplatin/paclitaxel or nab-paclitaxel (ORIENT-12, ESCORT-1st, RATIONALE-307); non-squamous NSCLC: domestic PD-1 + pemetrexed/carboplatin (ORIENT-11); gastric/GEJ cancer: nivolumab + FOLFOX/XELOX (CheckMate-649 — global, China approved); camrelizumab + CAPOX or FOLFOX (ESCORT-GASTRIC); sintilimab + CAPOX (ORIENT-16); esophageal squamous cell carcinoma: high incidence in China; camrelizumab + TP/PP (ESCORT); sintilimab + chemotherapy; pembrolizumab + chemotherapy (KEYNOTE-590); NPC: camrelizumab + GP chemotherapy (CAPTAIN-1, Chinese registration); hepatocellular carcinoma: atezolizumab + bevacizumab (IMbrave150 — global, China approved first-line); sintilimab + IBI305 (bevacizumab biosimilar) (ORIENT-32 — China specific registration); camrelizumab + rivoceranib (apatinib) (RESCUE — China approved); cervical cancer: camrelizumab + chemotherapy ± bevacizumab; Combination economics: each combination adding second drug cost; combination prescriptions significantly higher value than monotherapy; domestic PD-1 + Chinese generic chemotherapy: affordable combination; international PD-1 + bevacizumab: premium tier.

How is predictive biomarker testing used in China for immunotherapy selection? China immunotherapy biomarker testing landscape: PD-L1 testing: CPS (Combined Positive Score) and TPS (Tumor Proportion Score) testing growing; international guidelines requiring PD-L1 testing for certain indications (gastric — CPS ≥5 for nivolumab; NSCLC — TPS for pembrolizumab monotherapy); domestic PD-1 approvals sometimes without PD-L1 restriction (lower commercial barrier but less precision medicine); TMB (Tumor Mutational Burden): pembrolizumab FDA approval for TMB-high tumors; China validation of TMB testing ongoing; tissue TMB (Foundation Medicine) and blood TMB (Guardant) platforms available in China; MSI testing: MSI-H/dMMR testing for pembrolizumab; growing testing adoption; mismatch repair protein IHC as alternative to MSI-PCR; HER2 testing: for gastric cancer trastuzumab eligibility; China rapid HER2 testing infrastructure from gastric cancer burden; EGFR/ALK: for NSCLC targeted therapy selection; relevant for immunotherapy selection (EGFR-mutant NSCLC less immunotherapy-responsive); Testing infrastructure: PathO China (companion diagnostics company); burning issues: NMPA companion diagnostic approval requirements; domestic CDx platforms; affordability of NGS testing; Testing gaps: significant variation in biomarker testing rates between tier 1 and tier 3 hospitals; guideline-directed testing not universally implemented; Chinese regulatory push for companion diagnostics alongside drug approvals.

#ChinaImmunotherapy #CombinationImmunotherapy #ChinaPD1chemo #HCCimmunotherapy #NSCLCchina #ImmunotherapyCombinationChina